Abstract
Genes of the synovial sarcoma X breakpoint (SSX) family are expressed in different human tumors, including melanomas, but not in adult somatic tissues. Because of their specific expression at the tumor site, SSX-encoded Ags are potential targets for anticancer immunotherapy. In this study, we have analyzed CD4+ T cell responses directed against the Ag encoded by SSX-4. Upon in vitro stimulation of PBMC from four melanoma patients bearing Ag-expressing tumors with a pool of long peptides spanning the protein sequence, we detected and isolated SSX-4-specific CD4+ T cells recognizing several distinct antigenic sequences, mostly restricted by frequently expressed HLA class II alleles. The majority of the identified sequences were located within the Krüppel-associated box domain in the N-terminal region of the protein, indicating a high potential immunogenicity of this region. Together our data document the existence of CD4+ T cells specific for multiple SSX-4 derived sequences in circulating lymphocytes from melanoma patients and encourage further studies to assess the impact of SSX-4-specific T cell responses on disease evolution in cancer patients.
Cite
CITATION STYLE
Ayyoub, M., Merlo, A., Hesdorffer, C. S., Rimoldi, D., Speiser, D., Cerottini, J.-C., … Valmori, D. (2005). CD4+ T Cell Responses to SSX-4 in Melanoma Patients. The Journal of Immunology, 174(8), 5092–5099. https://doi.org/10.4049/jimmunol.174.8.5092
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.